Scientists test Triple-Threat attack on tough breast cancer
NCT ID NCT05422794
Summary
This early-stage trial is testing the safety of a new three-drug combination for people with advanced triple-negative breast cancer. It combines a new experimental pill (ZEN003694) with an immunotherapy drug (pembrolizumab) and a standard chemotherapy (nab-paclitaxel). The main goal is to find the safest dose and see if this combination can help shrink or stabilize the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
RECRUITINGBoston, Massachusetts, 02118, United States
Contact
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
RECRUITINGNew York, New York, 10016, United States
Contact
Contact Email: •••••@•••••
-
NYU Langone Hospital - Long Island
RECRUITINGMineola, New York, 11501, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt Breast Center at One Hundred Oaks
RECRUITINGNashville, Tennessee, 37204, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.